Tetracyclines: what a rheumatologist needs to know?
Identifieur interne : 001806 ( Main/Exploration ); précédent : 001805; suivant : 001807Tetracyclines: what a rheumatologist needs to know?
Auteurs : Suzan M. Attar [Arabie saoudite]Source :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2009-07.
English descriptors
- Teeft :
- Antibiotic, Arthritis, Arthritis rheum, Blood vessel formation, Bone formation, Bone metabolism, Calcinosis, Calcinosis deposit, Calcinosis size, Chronic reactive, Complete response, Cutaneous, Cutaneous calcinosis, Cutaneous sarcoidosis, Disease activity, Disease duration, Doxycycline, Doxycycline group, Endothelial cells, Functional status, Greater improvement, International journal, Intravenous doxycycline, Minocycline, Nitric oxide synthetase, Oral doxycycline, Partial response, Placebo, Placebo group, Primary outcome, Propionibacterium acnes, Randomized, Relevant articles, Rheum, Rheumatic, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatologist, Sarcoidosis, Saudi arabia, Seronegative arthritis, Seronegative spondyloarthritis, Skin hyperpigmentation, Skin lesions, Systemic sclerosis, Tetracycline, Undifferentiated spondyloarthropathy.
Abstract
Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.
Url:
DOI: 10.1111/j.1756-185X.2009.01389.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001793
- to stream Istex, to step Curation: 001793
- to stream Istex, to step Checkpoint: 000731
- to stream Main, to step Merge: 001810
- to stream Main, to step Curation: 001806
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tetracyclines: what a rheumatologist needs to know?</title><author><name sortKey="Attar, Suzan M" sort="Attar, Suzan M" uniqKey="Attar S" first="Suzan M." last="Attar">Suzan M. Attar</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DD1C98B17705F3B99DE713CD07D619DEBA850774</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1756-185X.2009.01389.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-BPXDG31X-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001793</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001793</idno><idno type="wicri:Area/Istex/Curation">001793</idno><idno type="wicri:Area/Istex/Checkpoint">000731</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000731</idno><idno type="wicri:doubleKey">1756-1841:2009:Attar S:tetracyclines:what:a</idno><idno type="wicri:Area/Main/Merge">001810</idno><idno type="wicri:Area/Main/Curation">001806</idno><idno type="wicri:Area/Main/Exploration">001806</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Tetracyclines: what a rheumatologist needs to know?</title><author><name sortKey="Attar, Suzan M" sort="Attar, Suzan M" uniqKey="Attar S" first="Suzan M." last="Attar">Suzan M. Attar</name><affiliation wicri:level="1"><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Medicine, King Abdulaziz University Hospital (KAUH), Jeddah</wicri:regionArea><wicri:noRegion>Jeddah</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">12</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="84">84</biblScope><biblScope unit="page" to="89">89</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2009-07">2009-07</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antibiotic</term><term>Arthritis</term><term>Arthritis rheum</term><term>Blood vessel formation</term><term>Bone formation</term><term>Bone metabolism</term><term>Calcinosis</term><term>Calcinosis deposit</term><term>Calcinosis size</term><term>Chronic reactive</term><term>Complete response</term><term>Cutaneous</term><term>Cutaneous calcinosis</term><term>Cutaneous sarcoidosis</term><term>Disease activity</term><term>Disease duration</term><term>Doxycycline</term><term>Doxycycline group</term><term>Endothelial cells</term><term>Functional status</term><term>Greater improvement</term><term>International journal</term><term>Intravenous doxycycline</term><term>Minocycline</term><term>Nitric oxide synthetase</term><term>Oral doxycycline</term><term>Partial response</term><term>Placebo</term><term>Placebo group</term><term>Primary outcome</term><term>Propionibacterium acnes</term><term>Randomized</term><term>Relevant articles</term><term>Rheum</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatologist</term><term>Sarcoidosis</term><term>Saudi arabia</term><term>Seronegative arthritis</term><term>Seronegative spondyloarthritis</term><term>Skin hyperpigmentation</term><term>Skin lesions</term><term>Systemic sclerosis</term><term>Tetracycline</term><term>Undifferentiated spondyloarthropathy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tetracyclines are broad‐spectrum antibiotics that act at the ribosomal level. They were first introduced in 1948 and were widely prescribed by dermatologists in the early 1950s for treatment of acne. More recently, biologic actions of tetracyclines affecting inflammation, angiogenesis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in rheumatic diseases have also been investigated. This article will review the rheumatological use of tetracycline and its analogues.</div></front></TEI><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Attar, Suzan M" sort="Attar, Suzan M" uniqKey="Attar S" first="Suzan M." last="Attar">Suzan M. Attar</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001806 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001806 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DD1C98B17705F3B99DE713CD07D619DEBA850774
|texte= Tetracyclines: what a rheumatologist needs to know?
}}
| This area was generated with Dilib version V0.6.33. |  |